Treatment Decisions in Multiple Myeloma

The New England Journal of Medicine published a comprehensive clinical-practice review on treatment decision-making in multiple myeloma, synthesizing current evidence across frontline and relapsed settings. The review, spanning 17 pages in the journal’s September 2026 issue, likely addresses evolving standards including quadruplet induction regimens, bispecific antibodies, and CAR-T sequencing in the treatment algorithm. As a tier-1 NEJM clinical review, it will serve as a key reference for hematologists navigating an increasingly complex therapeutic landscape for this plasma cell neoplasm.